MediciNova Shares Fall After Mixed Phase 2 Results for Fatty Liver Drug MN-001
MediciNova fell after mixed Phase 2 data for MN-001. HDL rose, but week-24 liver fat and triglycerides missed significance in 40 patients.
MediciNova fell after mixed Phase 2 data for MN-001. HDL rose, but week-24 liver fat and triglycerides missed significance in 40 patients.
Phase 2b/3 ALS data due Q4 2026; cash runway into late 2027.